October 5, 2015November 5, 2015

FDA Approves Combination Therapy of Gilead’s Letairis® Plus Eli Lilly’s Adcirca for patients with Pulmonary Arterial Hypertension

Gilead Sciences, recently announced that the FDA has approved of the use of Letairis® (ambrisentan) combined with tadalafil (marketed for PAH under the brand name Adcirca by Eli Lilly) to treat patients with ... Read more

August 31, 2015November 5, 2015

Gilead Sciences Publishes Data From AMBITION Study of Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

Gilead Sciences, Inc., a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical needs, recently announced detailed data from its AMBITION randomized, double-blind, multicenter ... Read more